Price Target Overview of Supernus Pharmaceuticals inc (NASDAQ:SUPN)

Supernus Pharmaceuticals inc (NASDAQ:SUPN) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.

Supernus Pharmaceuticals inc (NASDAQ:SUPN) lost -1.23 Percent and closed its previous trading session at $48.1. The stock traded with the average Volume of 827.09 Million at the end of last session.

Supernus Pharmaceuticals inc (NASDAQ:SUPN) has the Market Capitalization of 2.52 Billion. The Stock has its 52-week High of $61.25 and 52-Week Low of $33.30 and it touched its 52-week high on 06/29/18 and 52-Week Low on 11/07/17


The company reported its last earnings Actual EPS of $0.57/share. While, the analyst predicted that the company could provide an EPS of $0.43/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.14/share which shows an Earnings Surprise of 32.6 Percent.

Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Supernus Pharmaceuticals inc (NASDAQ:SUPN) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -9.91% where SMA50 and SMA200 are -11.95% and 4.93% respectively.

The company shows its Return on Assets (ROA) value of 14.8%. The Return on Equity (ROE) value stands at 26.7%. While it’s Return on Investment (ROI) value is 24.5%.

Supernus Pharmaceuticals inc (NASDAQ:SUPN) currently has a Weekly Volatility of 7.98% percent while its Monthly Volatility is at 4.37% percent. While talking about Performance of the Stock, Supernus Pharmaceuticals inc currently has a Weekly performance of -11.42%, monthly performance percentage is -9.16 percent, Quarterly performance is -3.61 percent, 6 months performance shows a percent value of 29.48% and Yearly Performance is 16.75 percent.

Company Profile:

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.